Glucagon-like peptide-1 (GLP-1) and, more recently, glucose-dependent insulinotropic polypeptide (GIP) and glucagon (Gcg) receptor (R) agonists have revolutionized T2DM and obesity treatment, restoring insulin sensitivity and often facilitating weight loss in patients [1,2]. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.